生物股在宣布其抗癌药物MTX240的制造合作后大幅上升. Biodexa shares surged after announcing a manufacturing partnership for its cancer drug MTX240.

周四, 在宣布与新能国际合作制造其抗癌药物MTX240后, Biodexa Pharmaceuticals的股价升. Biodexa Pharmaceuticals shares surged Thursday after announcing a manufacturing partnership with Syngene International for its cancer drug MTX240. 该公司计划提交IND申请,并开始对目前治疗耐药的患者进行临床研究. The company plans to file an IND application and start a clinical study for patients resistant to current treatments.